首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1728373

朊病毒疾病治療市場－全球產業規模、佔有率、趨勢、機會及預測，依類型（人類朊病毒疾病、動物朊病毒疾病）、藥物（抗憂鬱藥物、抗精神病藥物）、地區及競爭細分，2020-2030 年預測

Prion Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity & Forecast Segmented By Type (Human Prion Diseases, Animal Prion Diseases), By Drug (Antidepressant, Antipsychotic Agents), By Region and Competition, 2020-2030F

出版日期: 2025年05月16日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球朊病毒疾病治療市值為 49.7 億美元，預計到 2030 年將達到 64.7 億美元，預測期內複合年成長率為 4.49%。朊病毒病，又稱傳染性海綿狀腦病 (TSE)，是一種罕見的致命神經退化性疾病，由大腦中錯誤折疊的朊病毒蛋白的異常積累引起。這些疾病包括庫賈氏病 (CJD)、變異型庫賈氏病 (vCJD)、致死性家族性失眠症 (FFI) 等。在疾病意識增強、診斷方法改進以及旨在開發有效療法的研究措施增加的支持下，市場正在穩步擴張。雖然無法治愈，但目前的治療方法主要是支持性的，重點在於症狀管理和患者的生活品質。人類朊病毒疾病占主導地位，受較高盛行率和研究活動的推動。抗憂鬱藥物因其在控制神經和精神症狀方面的作用而成為領先的藥物類別。儘管存在診斷複雜性、發病率低和治療選擇有限等挑戰，但生物標記研究的創新、神經退化研究的資金以及先進治療方法的探索預計將進一步推動市場成長。

市場概覽
預測期	2026-2030
2024年市場規模	49.7億美元
2030年市場規模	64.7億美元
2025-2030 年複合年成長率	4.49%
成長最快的領域	人類先前疾病
最大的市場	北美洲

關鍵市場促進因素

朊病毒疾病的盛行率不斷上升

主要市場挑戰

對朊病毒疾病的了解有限

主要市場趨勢

新興治療方法

正在開發小分子來破壞朊病毒複製並降低神經毒性。
人們正在探索單株抗體結合和中和錯誤折疊的朊病毒蛋白的潛力。
基於 RNA 的療法，例如反義寡核苷酸 (ASO) 和 RNA 干擾 (RNAi)，旨在抑制異常朊病毒蛋白的產生或促進其分解。
包括 CRISPR-Cas9 在內的基因治療技術有望糾正導致遺傳性朊病毒疾病的基因突變。

這些治療創新雖然主要處於實驗階段，但為未來的疾病改良治療帶來了希望，並吸引了越來越多的投資和研究關注。

The Global Prion Disease Treatment Market was valued at USD 4.97 Billion in 2024 and is projected to reach USD 6.47 Billion by 2030, growing at a CAGR of 4.49% during the forecast period. Prion diseases, or transmissible spongiform encephalopathies (TSEs), are rare, fatal neurodegenerative disorders resulting from the abnormal accumulation of misfolded prion proteins in the brain. These include conditions such as Creutzfeldt-Jakob Disease (CJD), variant CJD (vCJD), Fatal Familial Insomnia (FFI), and others. The market is witnessing steady expansion, supported by greater disease awareness, improved diagnostics, and increased research initiatives aimed at developing effective therapies. While no cure exists, current treatment approaches are largely supportive, focusing on symptom management and patient quality of life. Human prion diseases are the dominant segment, driven by higher prevalence and research activity. Antidepressants represent the leading drug class due to their role in managing neurological and psychiatric symptoms. Innovations in biomarker research, funding for neurodegenerative studies, and exploration of advanced therapeutic methods are expected to further propel market growth, despite challenges such as diagnostic complexity, low incidence rates, and limited treatment options.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.97 Billion
Market Size 2030	USD 6.47 Billion
CAGR 2025-2030	4.49%
Fastest Growing Segment	Human Prior Diseases
Largest Market	North America

Key Market Drivers

Increasing Prevalence of Prion Diseases

The rising incidence of prion diseases globally is a major growth driver for the treatment market. These neurodegenerative disorders, though rare, are increasingly diagnosed due to advancements in medical technology and growing awareness among healthcare professionals. Enhanced diagnostic capabilities have made it possible to identify cases that were previously misdiagnosed or undetected, contributing to a perceived rise in prevalence. Additionally, the aging global population has amplified the incidence of diseases like sporadic CJD, which is more common in older adults. According to the National Library of Medicine, at least 485 cases of iatrogenic CJD (iCJD) have been documented worldwide, most of which occurred prior to 2012. These included cases linked to contaminated surgical tools, EEG needles, corneal transplants, and notably, human-derived growth hormones and dura mater grafts. As detection improves and awareness increases, the demand for prion disease treatments is expected to grow steadily.

Key Market Challenges

Limited Understanding of Prion Diseases

A major challenge hindering the development of effective prion disease therapies is the limited understanding of the diseases' underlying mechanisms. Prion disorders are complex, and their pathogenesis-particularly how prions replicate and cause neurodegeneration-remains only partially understood. This knowledge gap restricts the identification of viable drug targets and slows down therapeutic innovation. The intricacy of prion biology requires extensive research to unravel molecular pathways before advancing drug discovery. This lack of foundational understanding poses a significant barrier to the timely development and approval of effective treatments.

Key Market Trends

Emerging Therapeutic Approaches

Innovative treatment strategies are emerging as key trends in the prion disease treatment landscape. Researchers are investigating a range of novel approaches to halt or reverse disease progression.

Small molecules are being developed to disrupt prion replication and reduce neurotoxicity.
Monoclonal antibodies are being explored for their potential to bind and neutralize misfolded prion proteins.
RNA-based therapies, such as antisense oligonucleotides (ASOs) and RNA interference (RNAi), aim to suppress abnormal prion protein production or promote its breakdown.
Gene therapy techniques, including CRISPR-Cas9, show promise for correcting genetic mutations responsible for inherited prion disorders.

These therapeutic innovations, though largely in experimental phases, offer hope for disease-modifying treatments in the future and are attracting increasing investment and research attention.

Key Market Players

Fresenius SE & Co. KGaA
Elite Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Novartis AG
Merck KGaA
AstraZeneca PLC
Bristol-Myers Squibb Company
Cipla Ltd
Teva Pharmaceuticals
Abbott Laboratories

Report Scope:

In this report, the Global Prion Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prion Disease Treatment Market, By Type:

Human Prion Diseases
Animal Prion Diseases

Prion Disease Treatment Market, By Drug:

Antidepressant
Antipsychotic Agents

Prion Disease Treatment Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prion Disease Treatment Market.

Available Customizations:

Global Prion Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prion Disease Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Human Prion Diseases, Animal Prion Diseases)
- 5.2.2. By Drug (Antidepressant, Antipsychotic Agents)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Prion Disease Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Drug
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Prion Disease Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Drug
- 6.3.2. Canada Prion Disease Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Drug
- 6.3.3. Mexico Prion Disease Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Drug

7. Europe Prion Disease Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Drug
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Prion Disease Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Drug
- 7.3.2. United Kingdom Prion Disease Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Drug
- 7.3.3. Italy Prion Disease Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Drug
- 7.3.4. France Prion Disease Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Drug
- 7.3.5. Spain Prion Disease Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Drug

8. Asia-Pacific Prion Disease Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Drug
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Prion Disease Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Drug
- 8.3.2. India Prion Disease Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Drug
- 8.3.3. Japan Prion Disease Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Drug
- 8.3.4. South Korea Prion Disease Treatment Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Drug
- 8.3.5. Australia Prion Disease Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Drug

9. South America Prion Disease Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Drug
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Prion Disease Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Drug
- 9.3.2. Argentina Prion Disease Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Drug
- 9.3.3. Colombia Prion Disease Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Drug

10. Middle East and Africa Prion Disease Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Drug
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Prion Disease Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Drug
- 10.3.2. Saudi Arabia Prion Disease Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Drug
- 10.3.3. UAE Prion Disease Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Drug

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Prion Disease Treatment Market: SWOT Analysis

14. Competitive Landscape

14.1. Fresenius SE & Co. KGaA
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Elite Pharmaceuticals Inc
14.3. Ionis Pharmaceuticals Inc
14.4. Novartis AG
14.5. Merck KGaA
14.6. AstraZeneca PLC
14.7. Bristol-Myers Squibb Company
14.8. Cipla Ltd
14.9. Teva Pharmaceuticals
14.10. Abbott Laboratories